Showing results (401-410 of 439) with videos related to

Sort By:
Pageof 44
European Urology Oncology|March 24, 2024
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or BicalutamideMamta Parikh, Catherine Tangen, Maha H A Hussain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancerAnita L Sabichi, Seth P Lerner, E Neely Atkinson, et al.
European Urology Oncology|October 11, 2025
Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer GroupRoger Li, Patrick J Hensley, Marko Babjuk, et al.
European Urology|May 22, 2025
Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder CancerMarie-Pier St-Laurent, Parminder Singh, David J McConkey, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|February 22, 2025
Impact of prior antiplatelet therapy on safety and efficacy of alteplase in acute ischemic stroke: a systematic review and meta-analysisAhmed Naeem, Hesham Kelani, Hazem Mohamed Salamah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2023
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer GroupAshish M Kamat, Andrea B Apolo, Marek Babjuk, et al.
Nature Communications|July 7, 2019
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signalingBrian D Robinson, Panagiotis J Vlachostergios, Bhavneet Bhinder, et al.
JAMA Oncology|November 1, 2019
Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder CancerAndrea B Apolo, Matthew I Milowsky, Lauren Kim, et al.
Urologic Oncology|September 13, 2015
Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activityNoah M Hahn, Beatrice S Knudsen, Siamak Daneshmand, et al.
Nature Communications|February 14, 2024
The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancerChandra Sekhar Amara, Karthik Reddy Kami Reddy, Yang Yuntao, et al.
Pageof 44